Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Mellinghoff IK, et al. Among authors: zhu s. N Engl J Med. 2005 Nov 10;353(19):2012-24. doi: 10.1056/NEJMoa051918. N Engl J Med. 2005. PMID: 16282176 Free article.
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Cloughesy TF, et al. Among authors: zhu s. PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008. PLoS Med. 2008. PMID: 18215105 Free PMC article. Clinical Trial.
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee WK, Cloughesy TF, Mischel PS. Yoshimoto K, et al. Among authors: zhu s. Clin Cancer Res. 2008 Jan 15;14(2):488-93. doi: 10.1158/1078-0432.CCR-07-1966. Clin Cancer Res. 2008. PMID: 18223223
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS. Lu KV, et al. Among authors: zhu s. Cancer Res. 2009 Sep 1;69(17):6889-98. doi: 10.1158/0008-5472.CAN-09-0347. Epub 2009 Aug 18. Cancer Res. 2009. PMID: 19690143 Free PMC article.
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. Tanaka K, et al. Among authors: zhu s. Cancer Discov. 2011 Nov;1(6):524-38. doi: 10.1158/2159-8290.CD-11-0124. Epub 2011 Sep 13. Cancer Discov. 2011. PMID: 22145100 Free PMC article.
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. Gini B, et al. Among authors: zhu s. Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12. Clin Cancer Res. 2013. PMID: 24030701 Free PMC article.
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. Guo D, et al. Among authors: zhu s. Sci Signal. 2009 Dec 15;2(101):ra82. doi: 10.1126/scisignal.2000446. Sci Signal. 2009. PMID: 20009104 Free PMC article.
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. Guo D, et al. Among authors: zhu s. Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Cancer Discov. 2011. PMID: 22059152 Free PMC article.
17,803 results
You have reached the last available page of results. Please see the User Guide for more information.